Long title
A multicentre, open-label, single ascending dose, dose-ranging, phase I/Iia study to evaluate the safety and tolerability of an autologous antigen-specific chimeric antigen receptor T regulatory cell therapy (TX200-TR101) in living donor renal transplant recipients
Date receipt dossier
EudraCT number
2019-001730-34
Company / Sponsor
Sangamo therapeutics
Phase
I/II a
Treated organism
Humans
Indication category
Immunological rejection
Disease
Living donor renal transplant recipients
Therapeutic approach
Prevention
Genetic modification
chimeric antigen receptor specific to the donor HLA A*2
Method of transfer of nucleic acid of interest
Recombinant lentiviral vectors
Administered biological material
Autologous T-cells transduced with lentiviral vector expressing CAR specific to the donor HLA A*2
Route of administration
Intravenous
Locations in Belgium
Autologous T-cells transduced with lentiviral vector expressing CAR specific to the donor HLA A*2
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
TX-200-TR101